Alexion Pharma (ALXN) Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress

Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress

Long-term data evaluate the effectiveness of ULTOMIRIS® (ravulizumab-cwvz) in reducing the risk of thrombosis in PNH, the primary cause of organ damage and premature death in untreated patients

Accepted abstracts include new interim Phase 3 data studying the safety and efficacy of ULTOMIRIS in pediatric patients

BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:... More